Roche

News

Roche’s TIGIT drug linked to worse outcomes in NSCLC trial

Roche’s anti-TIGIT drug tiragolumab has failed a lung cancer study, denting enthusiasm for the programme just as there were signs that it was getting back on track after a series of disappo

News

FDA clears Roche digital pathology platform for diagnosis

Roche’s move into the digital pathology category has been boosted by FDA approval of a lab instrument and toolkit for use as an aid to clinical diagnosis.

News

FDA widens label for BMS’ cancer drug Augtyro

Bristol-Myers Squibb has claimed FDA approval for a new, tumour-agnostic indication for Augtyro, the cancer drug it acquired as part of its $4.1 billion takeover of Turning Point Therapeuti

News

Future of Pfizer’s Duchenne gene therapy in doubt

Pfizer is “evaluating appropriate next steps” for its Duchenne muscular dystrophy (DMD) gene therapy after it failed a phase 3 trial.

News

ALZpath licenses Alzheimer’s diagnosis tech to Roche

Diagnostics giant Roche is putting its weight behind a biomarker for Alzheimer’s disease developed by ALZpath.

News

Italy starts probe into Lucentis biosimilar delay allegation

Italy’s antitrust authority has launched an investigation against eight pharma companies, including Novartis and Roche, over suspicion they may have colluded to delay the

Roche’s TIGIT drug linked to worse outcomes in NSCLC trial

FDA clears Roche digital pathology platform for diagnosis

FDA widens label for BMS’ cancer drug Augtyro

Future of Pfizer’s Duchenne gene therapy in doubt

ALZpath licenses Alzheimer’s diagnosis tech to Roche

Italy starts probe into Lucentis biosimilar delay allegation

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

Roche

Editor's Picks